Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes by Skotheim, R.I. et al.
This is a repository copy of Novel genomic aberrations in testicular germ cell tumors by 
array-CGH, and associated gene expression changes.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/155490/
Version: Published Version
Article:
Skotheim, R.I., Autio, R., Lind, G.E. et al. (5 more authors) (2006) Novel genomic 
aberrations in testicular germ cell tumors by array-CGH, and associated gene expression 
changes. Analytical Cellular Pathology, 28 (5-6). 219786. pp. 315-326. ISSN 2210-7177 
https://doi.org/10.1155/2006/219786
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Cellular Oncology 28 (2006) 315–326 315
IOS Press
Novel genomic aberrations in testicular germ
cell tumors by array-CGH, and associated
gene expression changes
Rolf I. Skotheim a, Reija Autio b, Guro E. Lind a, Sigrid M. Kraggerud a, Peter W. Andrews c,
Outi Monni d, Olli Kallioniemi e and Ragnhild A. Lothe a,f,∗
a Department of Cancer Prevention, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical
Center, Oslo, Norway
b Institute of Signal Processing, Tampere University of Technology, Tampere, Finland
c Department of Biomedical Science, University of Sheffield, Sheffield, United Kingdom
d Biomedicum Biochip Center and Institute of Biomedicine, BioMedicum Helsinki, University of Helsinki, Helsinki,
Finland
e Medical Biotechnology Group, VTT Technical Research Centre of Finland and University of Turku, Turku,
Finland
f Department of Molecular Biosciences, University of Oslo, Oslo, Norway
Abstract. Introduction: Testicular germ cell tumors of adolescent and young adult men (TGCTs) generally have near triploid
and complex karyotypes. The actual genes driving the tumorigenesis remain essentially to be identified. Materials and Methods:
To determine the detailed DNA copy number changes, and investigate their impact on gene expression levels, we performed an
integrated microarray profiling of TGCT genomes and transcriptomes. We analyzed 17 TGCTs, three precursor lesions, and the
embryonal carcinoma cell lines, NTERA2 and 2102Ep, by comparative genomic hybridization microarrays (array-CGH), and
integrated the data with transcriptome profiles of the same samples. Results: The gain of chromosome arm 12p was, as expected,
the most common aberration, and we found CCND2, CD9, GAPD, GDF3, NANOG, and TEAD4 to be the therein most highly
over-expressed genes. Additional frequent genomic aberrations revealed some shorter chromosomal segments, which are novel
to TGCT, as well as known aberrations for which we here refined boundaries. These include gains from 7p15.2 and 21q22.2, and
losses of 4p16.3 and 22q13.3. Integration of DNA copy number information to gene expression profiles identified that BRCC3,
FOS, MLLT11, NES, and RAC1 may act as novel oncogenes in TGCT. Similarly, DDX26, ERCC5, FZD4, NME4, OPTN, and
RB1 were both lost and under-expressed genes, and are thus putative TGCT suppressor genes. Conclusion: This first genome-
wide integrated array-CGH and gene expression profiling of TGCT provides novel insights into the genome biology underlying
testicular tumorigenesis.
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1. Introduction
Testicular germ cell tumor (TGCT) is the most com-
mon malignancy among adolescents and young adult
men in Western industrialized countries, and the in-
cidence has increased dramatically over the past fifty
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years [5,8]. TGCT develops from precursor lesions
called intratubular germ cell neoplasia (IGCN, alias
carcinoma in situ; ref. [44]), believed to originate from
primordial germ cells during fetal life [45]. TGCT is
histologically classified into seminomas and nonsemi-
nomas, and nonseminomas are further subdivided into
embryonal carcinomas, choriocarcinomas, yolk sac tu-
mors, and teratomas [31].
The TGCT genome [reviewed in ref. 47] is gener-
ally hypo- to hyper-triploid [7,10,34]. Extra genomic
material of chromosome arm 12p, often in the form
of isochromosomes [4], is present in virtually all of
1570-5870/06/$17.00  2006 – IOS Press and the authors. All rights reserved
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these tumors [40,52], regardless of histological sub-
types. The application of comparative genomic hy-
bridization to metaphase spreads (chromosomal CGH)
has enabled genome-wide analysis of DNA copy num-
ber aberrations [16] at a resolution level of 5–10 Mbp.
Several reports of chromosomal CGH of the TGCT
genome have revealed many recurrent copy num-
ber gains and losses, and despite the morphological
and transcriptional distinctions between seminoma and
nonseminoma, they share many of the same genomic
aberrations, although frequencies may vary [21,23,29,
35,41,54,55].
Transcriptional profiling of TGCT has revealed ma-
jor differences at the gene expression levels between
all the histological subgroups [15,19,20,48,49], indi-
cating that the selective pressure on the different sub-
types may as well enforce different genetic aberra-
tions. However, this has not been reflected at the gross
genome level, as reported by previous chromosomal
CGH studies [47].
DNA microarrays are useful for measuring both
the gene expression [43] and DNA copy number lev-
els (array-CGH; [25,50]) in a genome-wide high-
resolution scale. Integration of these two high-through-
put technologies on the same set of samples gives a
possibility to identify the genetic mechanisms affect-
ing expression level changes of the target genes. In this
report, we present the integrative results of genome and
transcriptome profiling of a series of TGCTs, IGCN,
and cell lines. Within commonly altered genomic re-
gions, we identify key genes that show both the altered
DNA copy number and gene expression, and thus are
putative oncogenes or tumor suppressor genes.
2. Material and methods
2.1. Sample set
Altogether, 22 testicular germ cell neoplasms were
analyzed, including 17 TGCTs, 2 TGCT cell lines
(NTERA2 and 2102Ep, refs. [1,2]), and 3 pre-malig-
nant IGCN. All samples were from different individ-
uals. The TGCT tissue samples were selected in or-
der to contain a single histological subtype each, as
judged from examination of HE stained sections by a
reference pathologist (ref. [48], author V.M.A.), and to
cover the known histological subtypes (3 seminomas,
5 embryonal carcinomas, 1 choriocarcinoma, 4 yolk
sac tumors, and 4 teratomas). The IGCN samples were
from areas adjacent to invasive tumors. HE stained sec-
tions of these three samples demonstrated absence of
malignant cells, and that about 100, 50, and 10% of the
seminiferous tubuli were filled with IGCN cells.
Frozen tissue samples were ground in liquid N2, and
subsequently transferred to two tubes. DNA was ob-
tained from one sample part by the phenol/chloroform
extraction principle, and RNA was obtained from the
other identical part by using the TRIzol R© reagent (In-
vitrogen, Carlsbad, CA, USA).
2.2. CGH microarrays
DNA copy number analyses on cDNA microarrays
were performed as previously reported [38,60]. Briefly,
DNA samples were digested over night by AluI and
RsaI (Sigma-Aldrich, St. Louis, MO, USA) and puri-
fied by phenol/chloroform extraction and ethanol pre-
cipitation. Five micrograms of fragmented DNA were
labeled using the RadPrime DNA Labeling System (In-
vitrogen) in the presence of Cy3-dUTP for tumors/cell
lines and Cy5-dUTP (Amersham Biosciences, Piscat-
away, NJ, USA) for normal reference (pool of DNA
isolated from normal lymphocytes of two healthy
males). Labeled DNA was then purified using Mi-
crocon YM-30 centrifugal filter units (Millipore, Bil-
lerica, MA, USA) and 50 µg human Cot-1 DNA
(Invitrogen), 100 µg yeast tRNA (Invitrogen), and
20 µg of each of pd(A)40-60 and pd(T)12-18 (Amer-
sham Biosciences) were added before a new round
of spin-concentration/purification. SSC and SDS (final
concentrations of 3.4× and 0.3%, respectively) were
added, and the total mixture was placed onto cDNA
microarrays with 12557 unique cDNA clones (Agi-
lent Human 1; G4100AM; Agilent Technologies, Palo
Alto, CA, USA) and incubated at 65◦C over night in
a sealed humidified chamber. After the hybridization,
microarray slides were washed for 2 min in each of
0.1% SDS, 0.5× SSC/0.01% SDS, and 0.06× SSC so-
lutions.
2.3. Data processing, statistics and quality control
measurements
The fluorescence intensities at the targets were de-
tected by a confocal laser scanner (Agilent Tech-
nologies), and resulting images were processed using
the Feature Extraction software (version 6.1.1.1, Ag-
ilent Technologies). This included defining the spots,
measuring intensities, flagging spots with inadequate
measurements, subtracting local background, and lo-
cally weighted scatter plot smoothing (LOWESS) dye-
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normalization. For spots that were not flagged as hav-
ing inadequate measurements, ratios (sample over ref-
erence) of the processed intensities were used for fur-
ther analysis.
The gene annotation of the cDNA clones on the ar-
ray was updated according to the TIGR Resourcerer,1
and UniGene identifiers were used to extract chromo-
some and base pair positions according to the UCSC
Genome Browser.2 Subsequently, 10142 cDNA clones
were positioned and ordered along the genome se-
quence, giving an average spacing of 303 kb through-
out the human genome. There was a median of 283
cDNA clones per sample not meeting the quality
control criteria. These are for the respective samples
treated as missing values in the data set.
CGH-Plotter, a MATLAB toolbox for array-CGH
data analysis [3], was utilized for finding the gains and
losses within the data. The moving median window
was set to move across five clones, and the constant
used when the number of changes is calculated was set
to three. Gains and losses were scored when log-2 of
the resulting dp value were >0.1 and <–0.07, respec-
tively. An additional cut-off for genomic amplification
was set at 0.3.
A self versus self-hybridization was used as a con-
trol to measure the technical variability of the non-
altered regions in the genome. With the current set-
tings, this led to identification of 12 clones (2 regions)
of false positives among the 10142 clones (0.1% false
discovery rate). This is in sharp contrast to the average
of 2664 positive clones in the invasive TGCT samples
and 594 in the IGCN samples. A dye swap control hy-
bridization (reverse labeling of cell line and reference
DNA) of the NTERA2 was also performed with satis-
factory results, as the average difference between their
processed log2-values was 0.03.
2.4. Integration of genomic aberrations and gene
expression data
RNAs from the same sample set were hybridized
on Agilent Human 1A 22k oligo microarrays. The
transcriptome profiles have been published elsewhere
[48], and the raw data can be obtained from the
Gene Expression Omnibus at the National Center for
Biotechnology Information website3 (accession num-
1TIGR Resourcerer version 11.0 (December 2004), URL:
http://pga.tigr.org/tigr-scripts/magic/r1.pl
2UCSC, May 2004 assembly, URL: http://genome.ucsc.edu/
3URL: http://www.ncbi.nlm.nih.gov/geo/
ber GSE1818). For each oligo, the expression values
were divided by the median of the three normal sam-
ples included in that data set. For oligos that were
present as replicates on the microarray, we used me-
dian expression values for further analyses. Missing
values were imputed by use of the k nearest neigh-
bors algorithm (k = 10; J-Express v.2.0, MolMine,
Bergen, Norway). The matching genomic positions for
the DNA copy number and gene expression were re-
trieved using CGH Plotter v24 to integrate the DNA
and RNA level data on 12K cDNA and 22K oligo mi-
croarrays.
To evaluate the influence of DNA copy number aber-
rations (gains and losses) on gene expression, weights
were calculated with previously reported statistical
methods [14]. Briefly, for each gene, separate calcula-
tions were performed for genes underexpressed due to
DNA copy number loss and for genes overexpressed
due to DNA copy number gain. The difference between
the median expression values in samples with and
without aberrations were divided by the sum of their
standard deviations. In the case of gains, the weight
wG, was calculated for each gene as follows:
wG = [mG1 −mG0]/[σG1 + σG0],
where mG1, σG1, and mG0 and σG0 denote the means
(m) and standard deviations (σ) for the expression lev-
els for samples with gain (G1) and without gain (G0),
respectively. For association between DNA copy num-
ber loss and low gene expression, the weight wL was
calculated as follows:
wL = [mL0 −mL1]/[σL1 + σL0].
To assess the statistical significance of each weight,
10 000 random permutations of the label vector (ran-
dom assignment of 0 and 1) were performed. The prob-
ability that a gene had a larger or equal weight by ran-
dom permutation than the original weight was denoted
by α. A low α (<0.05) indicates a significant associa-
tion between gene expression and DNA copy number
aberrations.
We set three criteria for genes to be considered
as gained and overexpressed, or as lost and underex-
pressed in TGCT. First, genes had to have α-values
<0.05. Secondly, the genes had to be located within
regions of gain or loss seen in at least 25% of the sam-
ples. Thirdly, from these, only genes with more than
4URL: http://www.cs.tut.fi/∼bsmg/cgh_plotter.html
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two-fold different mean expression values, as com-
pared to the normal testicular tissues, were considered
for the eventual list of putative target genes for TGCT.
2.5. Statistical analysis of target genes on
chromosome arm 12p
Statistical analysis of 12p target genes was per-
formed differently because DNA copy number gain of
12p was present in all cancer samples, and because
calculation of α-values requires a group of samples
without the genetic aberration. Therefore, a two class
unpaired Significance Analysis of Microarrays (SAM;
ref. [58]) was performed comparing expression values
in the 21 samples found to have gain of 12p by array-
CGH with the three normal testis samples. A false dis-
covery rate of 0.05 was set as cut-off, and further, we
restricted the genes of interest only to include those
with more than three-fold higher average expression in
the tumors than in the normal testis.
2.6. Gene expression validation by quantitative
RT-PCR
For reverse transcriptase polymerase chain reaction
(RT-PCR), of the candidate genes FOS, MLLT11, and
RAC1, and the reference gene GUSB, new first-strand
cDNA was synthesized from 5 µg total RNAs of the
same sample set in a randomly primed polymerization
using a High Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA, USA). To quantify the re-
spective mRNA levels, ten ng of this cDNA was used
as template in real time PCR, utilizing the 7900HT
System (TaqMan; Applied Biosystems). Probe and
primer sets were pre-designed and ordered from Ap-
plied Biosystems (FOS, Hs00170630_m1; MLLT11,
Hs00199111_m1; RAC1, Hs01588892_g1; and GUSB,
4322171) and each gene was analyzed in triplicate for
all samples. The quantitative expression levels were
measured against a standard curve generated from di-
lutions of cDNA from the human universal reference
RNA (Stratagene). In order to adjust for the possi-
bly variable amounts of cDNA input in each PCR, we
normalized the expression quantity of the target genes
with the quantity of the endogenous control GUSB.
To facilitate the comparison between the TaqMan and
oligo microarray transcriptome data, changes in gene
expression relative to the normal tissues was calculated
by dividing the median of the three replicates by the
median expression from the normal samples.
3. Results
The DNA copy number gains and losses were iden-
tified by array-CGH from 22 testicular germ cell neo-
plasms, including 17 TGCTs, 2 TGCT cell lines, and 3
IGCN (precursor lesions). Both gains and losses were
identified within all testicular DNA samples. Genome-
wide frequencies and locations of gains and losses are
summarized in Fig. 1.
Gain from chromosome arm 12p was seen in all 19
TGCTs (including all invasive tumors and the two em-
bryonal carcinoma cell lines), and in two of the three
IGCN samples. The further most commonly gained
regions were of the whole or from parts of chro-
mosomes X (79%), 21 (74%), 7 (58%), 8, and 14
(42%). The most commonly lost regions were from
chromosomes 22 (68%), 4, 5, 13 (47%), 16, and Y
(42%). Many of these gains and losses span large
chromosomal regions, or even whole chromosomes.
But still, within this list of the most common aber-
rations, we identified the smallest regions of overlap-
ping gains, defined to include breakpoints detected in
at least three samples, at 7p11.2-ter (0–55.91 Mbp),
12p11.22-ter (0–28.00 Mbp), 21q21.3–22.2 (29.64–
39.75 Mbp), and losses at 4p16.3 (0–0.66 Mbp), 5p14-
ter (0–27.07 Mbp), 13q14.3-ter (52.52–114.15 Mbp),
16p13.3 (0–3.10 Mbp), 22q13.31-ter (45.25–
49.48 Mbp) (Table 1).
We considered the regions of DNA copy number
gain to be distinct high-level amplifications if at least
three samples exceeded three times the gain detection
threshold. In addition to 11 samples with high-level
amplifications at 12p, five samples had overlapping
amplifications at 21q22.2 (38.60–39.75 Mbp), four at
17p13.3 (1.27–1.34 Mbp), and three in each of 6p21.1
(43.15–43.30 Mbp), 7p15.2 (26.91–26.97 Mbp),
19q13.32 (53.31–53.77 Mbp), and Xp22.1-q13.1
(18.81–70.29 Mpb).
As a crude comparison of DNA copy number
changes to gene expression data, we first looked into
the whole chromosome arms with the highest fre-
quency of gains and losses, and compared expres-
sion levels of the therein-located genes. We found
overexpression (mean log2 value within tumor sam-
ples >0.5) of 35% of the genes located on the gen-
erally gained chromosome arm 12p. This is signifi-
cantly more than the frequency of 13% overexpressed
genes on the genome-wide level (Fisher’s exact test,
p = 5 × 10−16). Conversely, we found reduced ex-
pression (mean log2 < −0.5) of 37% of the genes lo-
cated on the generally lost chromosome arm 13q, as
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Fig. 1. The testicular germ cell tumor genome. Percentages of DNA copy number gains (red) and losses (green) from 19 testicular malignancies
(17 TGCTs and 2 TGCT cell lines) are shown. Vertical black lines indicate centromere positions.
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Table 1
Smallest regions of overlapping gains and losses. These genomic regions were identified by showing DNA
copy number changes in more than 40 percent of the samples and being limited by break points in at least
three tumors at each side. For each region, genes with DNA copy number associated expression are listed
Cytogenetic Pct. Mbp from Genes overexpressed in samples with gain/
map position p-telomere underexpressed in samples with loss
Gains
7p11.2-ter 58 0–55.91 C1GALT1, CCT6A, DFNA5, ECOP, IGFBP3, IMP-3,
LSM5, NDUFA4, RAC1, RP9, SEC61G, SNX10
12p11.22-ter∗ 100 0–28.00 CD9, CCND2, CGI-04, CGI-141, DERA, DRPLA,
FLJ20696, FLJ22662, GDF3, KCNJ8, KLRB1, KLRG1,
LDHB, LEPREL2, MGST1, MLF2, NANOG, PHC1, TEAD4
21q21.2-22.2 74 29.64–39.75 SFRS15
Losses
4p16.3 47 0–0.66
5p14-ter 47 0–27.07 LOC133957
13q14.3-ter 47 52.52–114.15 CLN5, DACH1, ERCC5, KCTD12, UCHL3, UGCGL2
16p13.3 42 0–3.10 NME4
22q13.31-ter 68 45.25–49.48
∗The chromosome 12p genes were selected through different criteria as the α-values can not be calculated
for genes where there are no samples without DNA copy number aberrations.
compared to 18% of the genes genome-wide (Fisher’s
exact test, p = 4× 10−12).
To identify genes which expression correlates to
the DNA copy number status of the same samples, a
stringent three-step statistical selection was performed.
There were 88 genes identified to be over-expressed
in samples with aCGH gain, and similarly, 46 genes
were identified showing under-expression with con-
comitant DNA copy number loss (Supplementary Ta-
ble 1). Genes among these that are located with the
herein identified smallest regions of overlapping gains
and losses are listed in Table 1. Three of the amplified
and overexpressed genes, FOS, MLLT11, and RAC1,
were validated by real-time RT-PCR with satisfactory
results (Table 2). Although the quantitative RT-PCR
expression values had a slightly different scale as com-
pared to the microarray data, the same association of
higher expression in samples with array-CGH gain was
seen for the three genes.
Criteria for detecting high-level expression of genes
on chromosome arm 12p are outlined in the methods
section, and among the resulting 16 genes, CCND2,
CD9, GAPD, GDF3, NANOG, and TEAD4 had the
highest fold over-expressions (Table 3). A dissection
of the gene expression levels of 12p-genes in TGCT is
illustrated in Fig. 2.
From the analyzed IGCN precursor lesions, no ge-
nomic region was altered in all three samples. Table 4
contains aberrations seen in two of the three IGCN,
along with the target genes whose median expression
in the IGCN was more than two-fold changed accord-
ingly as compared with the median expression in the
three normal testis samples.
4. Discussion
In the current study, we have integrated genome pro-
files with the transcriptome profiles of primary testic-
ular cancers of germ cell origin. Thereby, we iden-
tified novel gene targets with changes in expression
which are associated to, and may be caused by, DNA
copy number changes. Using array-CGH technology
to map the genomic aberrations in TGCT in detail,
we identified several novel loci of common DNA copy
number gains and losses. Previous genomic data ob-
tained by chromosome-based techniques are restricted
by the low resolution of the metaphase chromosomes.
Furthermore, the chromosome-CGH method do not
give reliable results at the telomere regions, which of-
ten lead to underscoring of common changes in these
chromosomal locations. Several of the herein detected
DNA copy number gains and losses have not previ-
ously been detected, most likely due to these technical
limitations.
The previously reported DNA copy number aberra-
tions in TGCT, obtained by chromosome-based meth-
ods, are in all essence gross gains and losses span-
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Table 2
Validation of FOS, MLLT11, and RAC1 as over-expressed genes in samples with array-CGH gain. The rank values
indicate the sort order of the samples based on the expression values (lowest rank numbers for samples with high-
est expression). Expression values from both real-time RT-PCR and oligo microarray analyses are relative to the
expression level in normal testis
FOS MLLT11 RAC1
microarray RT-PCR microarray RT-PCR microarray RT-PCR
Average rank
gain 8.4 7.4 6.7 6.8 10.1 11.3
no gain 15.3 15.5 18.2 18.2 18.9 17.7
Median expression
gain 7.9 13.9 4.9 11.1 8.4 2.3
no gain 1.2 1.2 1.1 2.1 1.6 1.4
Table 3
Significantly overexpressed genes on chromosome arm 12p
Symbol Gene name d-score Fold change Cytoband Mbp from pter
TEAD4 TEA domain family member 4 2.39 5.15 12p13.33 2.94
CCND2 cyclin D2 2.70 6.66 12p13.32 4.25
CD9 CD9 antigen (p24) 2.25 8.38 12p13.31 6.21
GAPD glyceraldehyde-3-phosphate dehydrogenase 2.02 12.19 12p13.31 6.52
MLF2 myeloid leukemia factor 2 1.96 3.43 12p13.31 6.73
LEPREL2 leprecan-like 2 2.07 3.16 12p13.31 6.81
GDF3 growth differentiation factor 3 1.61 6.22 12p13.31 7.73
NANOG Nanog homeobox 1.50 4.16 12p13.31 7.83
KLRB1 killer cell lectin-like receptor subfamB, memb1 1.98 3.32 12p13.31 9.64
FLJ22662 hypothetical protein FLJ22662 1.74 4.03 12p13.1 14.55
DERA 2-deoxyribose-5-phosphate aldolase homolog 2.38 3.28 12p12.3 16.08
MGST1 microsomal glutathione S-transferase 1 1.75 3.86 12p12.3 16.41
GOLT1B golgi transport 1 homolog B 2.27 3.31 12p12.1 21.55
LDHB lactate dehydrogenase B 1.88 3.23 12p12.1 21.68
KCNJ8 potassium inwardly-rectifying ch, subfamJ, memb8 2.04 3.75 12p12.1 21.81
CGI-04 CGI-04 protein 2.23 3.22 12p11.21 32.79
Table 4
Genetic changes in intratubular germ cell neoplasia. DNA copy number changes seen in at least two of the three
IGCN are shown together with their associated gene expression changes
Cytogenetic Mbp from Gained and overexpressed/lost and
map position p-telomere underexpressed genes
Gains
12pter-q12 0–45.90 C1R, C1S, CCND2, CLEC2, CLECSF8, DERA, ELKS, FLJ20696,
FLJ22662, GRCC9, KCNA1, KCNJ8, KLRB1, KLRF1, KRAS2,
LAG3, MGP, NANOG, PIK3C2G, PPFIBP1, SSPN, TEAD4
15q11-13.1 0–27.20 GABRB3
21q21.3-22.11 29.83–33.56 GRIK1
Xp11.23-ter 0–46.81 ACE2, ATP6AP2, EFHC2, EGFL6, PPEF1, RAI2, S100G, SAT
Losses
4p16.3 0–0.66
10q26.2-ter 129.14–135.48 C10orf92, VENTX2
18p11.32 0–0.15
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Fig. 2. Over-expression of genes located on chromosome arm 12p. Genes located in the upper part of the chart have higher expression in TGCTs
than in normal testicular tissues. The significance of the association is implicated by the size of the circles (the bigger the circle, the more
significant the association). Genes in the right part of the figure have a higher expression in undifferentiated stem cell-like histological subtypes
(seminomas and embryonal carcinomas) than in more differentiated types (choriocarcinoma, yolk sac tumor, and teratoma). Our hypothesis is
that the genes in the upper-right corner are likely to be target “driving genes” of the 12p-amplifications of TGCTs.
ning several chromosomal bands, or even entire chro-
mosomes [47]. This was also the case in the current
data set in which gains of whole or parts of chromo-
somes 7, 8, 12, 14, 21, and X, and losses from whole or
parts of 4, 5, 13, 16, 22, and Y were the most frequent
aberrations. However, in some tumors, these aberra-
tions covered smaller regions, and due to the improved
resolution of array-CGH compared to chromosome-
based CGH, we were able to narrow down some of
these regions and describe their smallest regions of
overlapping gains and losses in TGCT. These include
for example the smallest region of overlapping gains
at 21q21.2-22.2, and overlapping losses at 4p16.3 and
22q13.31-ter.
In addition to these mostly gross chromosomal
changes, we discovered frequent losses of several
small subtelomeric regions. These regions have not
been described previously because chromosomal CGH
does neither have the sufficient resolution nor provide
reliable results close to the telomeres. One explana-
tion may be that the subtelomeric losses occur due to
telomere shortening. However, these aberrations were
not randomly distributed across the telomeres, since
sequences close to the 4p-telomere were lost in 47% of
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the malignancies, whereas several other subtelomeric
regions were retained in all samples (Fig. 1).
One recent study has also used array-CGH to de-
tect aberrations in TGCT [27]. In that study, 11 sam-
ples, mainly seminomas, were analyzed on 5k cDNA
microarrays, and there were no accompanying expres-
sion data. Two previous reports of combined DNA
and RNA level measurements in TGCT limited their
analyses to genes located on chromosome arm 12p [6,
61]. Thus, to our knowledge, the present study is the
first genome-wide analysis with integration of both the
DNA and RNA level information in TGCT.
We identified 88 genes that were both frequently
gained and overexpressed in a correlated manner. Simi-
larly, 46 genes with DNA copy number loss and under-
expression were identified. Through gene set analy-
ses,5 the enriched categories for the gained and over-
expressed genes included the terms “proto-oncogene”
(including the genes BRCC3, FOS, MLLT11, and
RAC1), “NF-κB cascade” (BCL10, ECOP, GOLT1B
(alias GCT2; ref. [6]), NFKBIA, and TSPAN6), and
“morphogenesis” (ATN1, BMP4, CD9, CYR61,
IGFBP3, IMP-3, LMNA, NES, NRXN3, RAC1, RPL10A,
TEAD4 and TPD52). Similarly, for the lost and under-
expressed genes, the enriched categories included “dis-
ease mutation” (CLN5, CRYAB, ERCC5, FZD4, PTS,
and RB1) and “DNA binding” (DACH1, ERCC5,
GTF2F2, HSFY2, PRKRIR, RB1, and ZFP28).
The proto-oncogenes FOS and RAC1 were both
gained and over-expressed in our data, suggesting that
increased activity of these down-stream RAS effectors
may be a selective advantage for malignant germ cells.
This adds to the growing evidence of the RAS pathway
as an ubiquitously and ectopically stimulated pathway
in TGCT. Although rare, activating mutations of KRAS
have been reported by us and others [32,33,39]. Also,
the effector RASSF1A has been shown inactivated by
an epigenetic mechanism in a significant subgroup of
TGCT [13,17,22]. Furthermore, the up-stream of RAS
tyrosine kinase receptor KIT have been found mutated
in TGCT, typically in bilateral cases [18,24,56]. KIT
has also been found amplified in some TGCTs, prefer-
ably in the seminoma subtype [26]. Amplifications at
this locus were not detected within the current sample
set. Finally, the overexpression of GRB7 in TGCT [28,
46,49], which protein binds both KIT and RAS [57,
59], suggests an ubiquitous deregulation of this path-
way.
5Database for Annotation, Visualization and Integrated Discovery
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A gene such as RB1 has previously been suggested
to play a role in the etiology of testicular tumorige-
nesis through its loss of expression and location on
the frequently lost chromosome 13 [37,51]. Although
RB1 appeared on the current list of jointly deleted and
under-expressed genes, it is located outside the identi-
fied smallest region of overlapping losses, in that five
samples displayed losses restricted distally to RB1.
The DNA excision repair gene ERCC5 is an interest-
ing candidate among the concomitantly lost and under-
expressed genes within this region.
DNA copy number gain of the chromosome arm
12p was detected in all malignant samples, and be-
cause this data set includes all histological subtypes of
TGCT, this is indicative of 12p gain as an early tu-
morigenic event. But, again, because 12p gain is not
ubiquitously present in all the precursor lesions [36,
42,55, and current data], we believe that having ex-
tra 12p-copies would at least also give selective ad-
vantage for cells of the histological subtypes thought
to originate as derivatives from IGCN, that is, the un-
differentiated histological subtypes seminoma and em-
bryonal carcinoma. The more differentiated subtypes
of TGCT (choriocarcinomas, yolk sac tumors, and ter-
atomas) are believed to be derivatives of the undif-
ferentiated embryonal carcinomas. Thus, having extra
12p-copies does not necessarily be of similar selective
advantage after the tumor cells differentiate. Genes that
are either highly over-expressed and/or having higher
expression in undifferentiated than in differentiated
TGCTs, are marked out in the Fig. 2. The latter include
BCAT1, CD9, FLJ22662, GAPD, GDF3, NANOG, and
TEAD4. Among these, BCAT1, GDF3, and MGST1,
are most highly expressed in embryonal carcinomas,
whereas GAPD is most highly expressed in semino-
mas. CCND2 is the most highly overexpressed gene at
12p that do not have differentiation-specific expression
levels. The latter is in agreement with a recent study
reporting ubiquitous over-expression of CCND2 in all
histological subtypes of TGCT [20].
The 12p amplifications, seen in virtually all TGCTs,
are generally a result of isochromosomes of the 12p
chromosome arm [4], although 12p-amplifications also
occur through other mechanisms [40,52]. In the pres-
ent array-CGH data set, we detected uniform amplifi-
cation levels along the length of the 12p chromosome
arm in all samples. However, a few cases have been
reported with a smaller amplified region at 12p12.1
[30,53,61] or with increased levels of amplification at
the 12p13 chromosome band [12,23,40]. Out of the
nine highlighted genes in Fig. 2, only BCAT1 is local-
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ized within the 12p12.1 region, whereas CCND2, CD9,
FLJ22662, GAPD, GDF3, NANOG, and TEAD4 are all
localized in the distal region of 12p. We have previ-
ously shown by both in vivo and in vitro studies that
three of these genes, CD9, GDF3, and NANOG, are
highly expressed in undifferentiated TGCTs, but are
significantly downregulated as embryonal carcinomas
differentiate [48]. Furthermore, all these three genes
were implicated in two recent studies [11,20] which
concluded that there is a cluster of stem cell-related
genes at 12p13 whose down-regulated gene expression
is associated to differentiation in TGCT. Together, this
speaks for the importance of the pluripotency-related
12p13 genes, both playing roles in the initiation of the
TGCT development through their over-expression, and
in the subsequent differentiation steps of TGCT cells
through their silencing.
Genomes of human embryonic stem cells have also
been found to contain DNA copy number aberrations.
Interestingly, these were extra copies of the chromo-
some arms 12p and 17q [9]. The fact that net gain of
12p sequences is a pathognomonic marker for germ
cell tumors and that gain of 17q is also common in
TGCT [23,49] is yet another line of evidence for these
stem-cell specific genes being the target genes on the
12p amplification – as well as evidence for GCT as
a caricature-model for early embryogenesis. In the
present series, 17q gain was detected in five of the 22
samples. This frequency is lower than in our previous
study using chromosomal CGH (22/33 samples), a dis-
crepancy which may be coincidental in small samples
series. Five samples in the present series were overlap-
ping with the previous study, and none of these showed
17q gain in neither of the studies.
In summary, we have pinpointed many novel re-
gions of DNA copy number aberrations in the TGCT
genome. These non-random genomic aberrations are
likely to give the tumor cells selective advantage, and
thus, the affected genes that are also altered in expres-
sion levels, are strong candidates to play roles in the
molecular etiology of TGCT. These genes include the
proto-oncogenes FOS and RAC1, showing both DNA
copy number gain and over-expression in TGCT. We
also provide evidence for the importance of amplifica-
tion and over-expression of 12p13 genes, both in the
initiation and differentiation of TGCT.
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